Contact
searchSearch
HMP Global
Login
Quiz
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
04/04/2024
True or False: Results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial demonstrated that tisotumab vedotin in the second-/third-line setting significantly improved survival and response outcomes compared to chemotherapy for patients with...
True or False: Results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial demonstrated that tisotumab vedotin in the second-/third-line setting significantly improved survival and response outcomes compared to chemotherapy for patients with...
True or False: Results from the...
04/04/2024
Oncology
Sudha Sundar, MBBS, MPhil
Conference Coverage
Refining Ovarian Cancer Test Accuracy Scores for Post-Menopausal Patients With Suspected Ovarian Cancer
04/02/2024

Featuring Sudha Sundar, MBBS, MPhil 

Featuring Sudha Sundar, MBBS, MPhil  ...
Sudha Sundar, MBBS, MPhil, discussed results from the ROCkeTS study, as presented at the SGO 2024 Annual Meeting, which compared the accuracy of various risk prediction models for diagnosing ovarian cancer.
Sudha Sundar, MBBS, MPhil, discussed results from the ROCkeTS study, as presented at the SGO 2024 Annual Meeting, which compared the accuracy of various risk prediction models for diagnosing ovarian cancer.
Sudha Sundar, MBBS, MPhil,...
04/02/2024
Oncology
Aine Clements, MD
Conference Coverage
Molecular Classification With Modified ProMisE Algorithm Predicts Survival Outcomes Among Patients With Endometrial Cancer
04/01/2024

Featuring Aine Clements, MD

Featuring Aine Clements, MD
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed...
04/01/2024
Oncology
Alison Schhram, MD
Conference Coverage
Rezatapopt Demonstrated Promising Efficacy Among Heavily Pre-Treated Patients With Advanced Ovarian Cancer
04/01/2024

Featuring Alison Schram, MD

Featuring Alison Schram, MD
At the SGO 2024 Annual Meeting, Alison Schram, MD, discussed results from the PYNNACLE study which assessed the clinical efficacy of rezatapopt among heavily pre-treated patients with advanced ovarian cancer harboring a TP53-Y220C mutation.
At the SGO 2024 Annual Meeting, Alison Schram, MD, discussed results from the PYNNACLE study which assessed the clinical efficacy of rezatapopt among heavily pre-treated patients with advanced ovarian cancer harboring a TP53-Y220C mutation.
At the SGO 2024 Annual Meeting,...
04/01/2024
Oncology
Conference Coverage
Dostarlimab Plus Chemotherapy Followed by Dostarlimab Plus Niraparib Maintenance Significantly Improved PFS Among Patients With Primary Advanced or Recurrent Endometrial Cancer
03/27/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 RUBY trial, dostarlimab plus carboplatin and paclitaxel followed by dostarlimab and niraparib significantly improved PFS among patients with primary advanced or recurrent endometrial cancer.
According to results from the phase 3 RUBY trial, dostarlimab plus carboplatin and paclitaxel followed by dostarlimab and niraparib significantly improved PFS among patients with primary advanced or recurrent endometrial cancer.
According to results from the...
03/27/2024
Oncology
Conference Coverage
Innovative, Non-Surgical Therapy APL-1702 Demonstrated Efficacy, Safety Among Patients With Cervical Histologic High-Grade Squamous Intraepithelial Lesions
03/26/2024

Stephanie Holland 

Stephanie Holland 
A phase 3 study found treatment with APL-1702 had long-term efficacy and safety among patients with cervical histologic high-grade squamous intraepithelial lesions.
A phase 3 study found treatment with APL-1702 had long-term efficacy and safety among patients with cervical histologic high-grade squamous intraepithelial lesions.
A phase 3 study found treatment...
03/26/2024
Oncology
Conference Coverage
Potential of Tazemetostat for Patients With ARID1A-Mutated Ovarian Clear Cell Carcinoma
03/25/2024

Stephanie Holland

Stephanie Holland
According to results from the phase 2 NRG-GY014 trial, tazemetostat failed to show efficacy among patients with endometrioid endometrial carcinoma or ovarian clear cell carcinoma without ARID1A mutations. However, there was potential noted...
According to results from the phase 2 NRG-GY014 trial, tazemetostat failed to show efficacy among patients with endometrioid endometrial carcinoma or ovarian clear cell carcinoma without ARID1A mutations. However, there was potential noted...
According to results from the...
03/25/2024
Oncology
Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Conference Coverage
Individualized Starting Dose of Niraparib Maintenance Therapy for Patients With Platinum-Sensitive Recurrent Ovarian Cancer
03/21/2024

Jordan Kadish 

Jordan Kadish 
According to results from the phase 3 NORA trial, presented at the 2024 SGO meeting, an individualized starting dose of niraparib in the maintenace setting yielded a favorable overall survival trend, compared to placebo, among patients with...
According to results from the phase 3 NORA trial, presented at the 2024 SGO meeting, an individualized starting dose of niraparib in the maintenace setting yielded a favorable overall survival trend, compared to placebo, among patients with...
According to results from the...
03/21/2024
Oncology
Brian M. Slomovitz, MD
Conference Coverage
Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer
03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting,...
03/18/2024
Oncology
Conference Coverage
Camrelizumab Plus Famitinib Improves Survival Outcomes for Patients With Recurrent or Metastatic Cervical Cancer
03/17/2024

Allison Casey

Allison Casey
According to phase 2 results, camrelizumab plus famitinib improved survival outcomes among patients with recurrent/metastatic cervical cancer, compared with camrelizumab alone and investigators choice of chemotherapy.
According to phase 2 results, camrelizumab plus famitinib improved survival outcomes among patients with recurrent/metastatic cervical cancer, compared with camrelizumab alone and investigators choice of chemotherapy.
According to phase 2 results,...
03/17/2024
Oncology
Conference Coverage
Addition of Induction Chemotherapy to Chemoradiation Improves Survival Outcomes Among Patients with Locally Advanced Cervical Cancer
03/17/2024

Allison Casey

Allison Casey
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial,...
03/17/2024
Oncology
David Cibula, MD, PhD
Conference Coverage
Sentinel Lymph Node Biopsy Without Systematic Pelvic Lymphadenectomy is Safe, Effective for Patients With Early-Stage Cervical Cancer
03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting,...
03/17/2024
Oncology
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
Conference Coverage
Atezolizumab Plus Bevacizumab and Chemotherapy As New First-Line Treatment Option for Recurrent or Metastatic Cervical Cancer
03/16/2024

Allison Casey

Allison Casey
According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...
According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...
According to results from a...
03/16/2024
Oncology
Conference Coverage
Tisotumab Vedotin Improves Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer
03/16/2024

Amber Denham

Amber Denham
Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...
Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...
Tisotumab vedotin demonstrated a...
03/16/2024
Oncology
Michael Goodheart, MD, University of Iowa, Iowa City, Iowa
Videos
Identifying Effective Treatment Combinations for Low-Grade Serous Ovarian Cancer
05/12/2023
Michael Goodheart, MD, and Adam Dupuy, PhD, discuss the use of CRISPR technology to identify new potential treatment combinations for low-grade serous ovarian cancer.
Michael Goodheart, MD, and Adam Dupuy, PhD, discuss the use of CRISPR technology to identify new potential treatment combinations for low-grade serous ovarian cancer.
Michael Goodheart, MD, and Adam...
05/12/2023
Oncology
BJ Rimel, MD, Cedar Sinai Medical Center, Los Angeles, California
Videos
Cancer-Related Concerns for Transgender and Special Patient Populations
05/12/2023
At the SGO Annual Meeting on Women’s Cancer BJ Rimel, MD, covers cancer-related concerns for transgender and special patient populations.
At the SGO Annual Meeting on Women’s Cancer BJ Rimel, MD, covers cancer-related concerns for transgender and special patient populations.
At the SGO Annual Meeting on...
05/12/2023
Oncology
Aaron Praiss, MD, Memorial Sloan Kettering Cancer Center, New York, New York
Videos
Surgical Stress May Promote IL-6–Driven Tumor Progression in High-Grade Serous Ovarian Cancer
05/11/2023
At the SGO Annual Meeting on Women’s Cancer, Aaron Praiss, MD discusses the role surgical stress can play in promoting IL-6–driven tumor progression in high-grade serous ovarian cancer.
At the SGO Annual Meeting on Women’s Cancer, Aaron Praiss, MD discusses the role surgical stress can play in promoting IL-6–driven tumor progression in high-grade serous ovarian cancer.
At the SGO Annual Meeting on...
05/11/2023
Oncology
Ayesha Alvero, MD, C.S. Mott Center at Wayne State University, Detroit, Michigan
Videos
Novel Immunomodulatory Virus CARG-2020 for Recurrent Ovarian Cancer
05/10/2023
At the SGO Annual Meeting on Women’s Cancer, Ayesha Alvero, MD, discusses CARG-2020, and how it may be used to restore immunosurveillance and establish anti-tumoral immunological memory among patients with ovarian cancer.
At the SGO Annual Meeting on Women’s Cancer, Ayesha Alvero, MD, discusses CARG-2020, and how it may be used to restore immunosurveillance and establish anti-tumoral immunological memory among patients with ovarian cancer.
At the SGO Annual Meeting on...
05/10/2023
Oncology
Rebekah Peplinski, graduate research assistant and PhD candidate, University of Iowa, Iowa City, Iowa
Videos
Identifying Oncogenic Drivers Related to Tumor Progression in High-Grade Ovarian Cancer
05/08/2023
At the SGO Annual Meeting on Women’s Cancer, Rebekah Peplinski, PhD candidate, discusses the potential role of Sleeping Beauty mutagenesis for identifying and understanding genes related to tumor progression in high-grade ovarian cancer.
At the SGO Annual Meeting on Women’s Cancer, Rebekah Peplinski, PhD candidate, discusses the potential role of Sleeping Beauty mutagenesis for identifying and understanding genes related to tumor progression in high-grade ovarian cancer.
At the SGO Annual Meeting on...
05/08/2023
Oncology
Allison Asante, PA-C, Northwell Health
Videos
Clinical Considerations for Oncologists Treating Transgender Patients
05/03/2023
Allison Asante, PA-C, discusses the key points from their presentation at the 2023 SGO Annual Meeting on Women’s Cancer on considerations when treating transgender patients.
Allison Asante, PA-C, discusses the key points from their presentation at the 2023 SGO Annual Meeting on Women’s Cancer on considerations when treating transgender patients.
Allison Asante, PA-C, discusses...
05/03/2023
Oncology
Neil Horowitz, MD, Dana-Farber Cancer Institute, Boston, MA
Videos
Concurrent Chemoradiation for Locally Advanced Vulvar Cancers
05/02/2023
At the SGO Annual Meeting on Women’s Cancer, Neil Horowitz, MD, discusses the efficacy of concurrent gemcitabine-cisplatin and intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the vulva.
At the SGO Annual Meeting on Women’s Cancer, Neil Horowitz, MD, discusses the efficacy of concurrent gemcitabine-cisplatin and intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the vulva.
At the SGO Annual Meeting on...
05/02/2023
Oncology
Jyoti Mayadev, MD, University of California - San Diego, CA
Videos
Efficacy and Safety of Chemoradiation for Patients With Stage IB3 Cervical Cancer
04/28/2023
At the SGO Annual Meeting on Women’s Cancer, Jyoti Mayadev, MD, discusses best practices for treating patients with IB3 cervical cancer, focusing on the benefits of chemoradiation treatment.
At the SGO Annual Meeting on Women’s Cancer, Jyoti Mayadev, MD, discusses best practices for treating patients with IB3 cervical cancer, focusing on the benefits of chemoradiation treatment.
At the SGO Annual Meeting on...
04/28/2023
Oncology
Sarah Lee, MD, NYU Langone Health, New York, NY
Videos
Effect of TMB, MSI-H, and MMR Status on Clinical Outcomes in Endometrial Cancer
04/06/2023
Sarah Lee, MD, presents data at the SGO Annual Meeting on Women’s Cancers examining the effect high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency may have on clinical outcomes of patients with...
Sarah Lee, MD, presents data at the SGO Annual Meeting on Women’s Cancers examining the effect high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency may have on clinical outcomes of patients with...
Sarah Lee, MD, presents data at...
04/06/2023
Oncology
Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark
Videos
First-Line Dostarlimab Plus Chemotherapy for Endometrial Cancer
04/06/2023
At the SGO Annual Meeting on Women’s Cancer, Mansoor Raza Mirza, MD, presents the results of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial, investigating the efficacy of dostarlimab plus chemotherapy in the first line for endometrial cancer.
At the SGO Annual Meeting on Women’s Cancer, Mansoor Raza Mirza, MD, presents the results of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial, investigating the efficacy of dostarlimab plus chemotherapy in the first line for endometrial cancer.
At the SGO Annual Meeting on...
04/06/2023
Oncology
Joyce Barlin, MD, Women’s Cancer Care Associates, Albany, NY
Videos
Chemotherapy and Radiation Sandwich Therapy vs Standard of Care for Advanced Endometrial Cancer
04/05/2023
Joyce Barlin, MD, presents data from the Lunchbox trial at the SGO Annual Meeting on Women’s Cancer, comparing chemotherapy and radiation sandwich therapy vs chemotherapy alone for patients with advanced endometrial cancer.
Joyce Barlin, MD, presents data from the Lunchbox trial at the SGO Annual Meeting on Women’s Cancer, comparing chemotherapy and radiation sandwich therapy vs chemotherapy alone for patients with advanced endometrial cancer.
Joyce Barlin, MD, presents data...
04/05/2023
Oncology
Jung-Yun Lee, MD, Yonsei University
Videos
Durvalumab Plus Tremelimumab Added to Frontline Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
03/30/2023
Jung-Yun Lee, MD, discusses the final primary analysis from a phase 2 study that explored durvalumab plus tremelimumab added to frontline neoadjuvant chemotherapy for patients with advanced ovarian cancer.
Jung-Yun Lee, MD, discusses the final primary analysis from a phase 2 study that explored durvalumab plus tremelimumab added to frontline neoadjuvant chemotherapy for patients with advanced ovarian cancer.
Jung-Yun Lee, MD, discusses the...
03/30/2023
Oncology
Lilian Gien, MD, Sunnybrook Odette Cancer Center
Impact of Tumor Size on Surgical Approach and Outcomes for Patients With Cervical Cancer
03/30/2023
Lilian Gien, MD, discusses results from an analysis exploring the associated between tumor size and oncologic outcomes among patients with cervical cancer undergoing minimally invasive and open radical hysterectomy.
Lilian Gien, MD, discusses results from an analysis exploring the associated between tumor size and oncologic outcomes among patients with cervical cancer undergoing minimally invasive and open radical hysterectomy.
Lilian Gien, MD, discusses...
03/30/2023
Oncology
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami, FL
Videos
Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Cancer
03/26/2023
Brian Slomovitz, MD, discusses his presentation on the use of letrozole plus ribociclib for patients with recurrent low-grade serous carcinoma of the ovaries at the SGO Annual Meeting on Women's Cancer.
Brian Slomovitz, MD, discusses his presentation on the use of letrozole plus ribociclib for patients with recurrent low-grade serous carcinoma of the ovaries at the SGO Annual Meeting on Women's Cancer.
Brian Slomovitz, MD, discusses...
03/26/2023
Oncology
Quiz
Quiz: VIGIL as Maintenance Therapy in Ovarian Cancer
03/29/2022
True or false: VIGIL (maintenance gemogenovatucel-T) in upfront maintenance therapy for ovarian cancer displays excellent tolerability that is ideal for maintenance therapy.
True or false: VIGIL (maintenance gemogenovatucel-T) in upfront maintenance therapy for ovarian cancer displays excellent tolerability that is ideal for maintenance therapy.
True or false: VIGIL...
03/29/2022
Oncology
Quiz
Quiz: Which Immunotherapy First Demonstrated Statistically Significant Survival Benefit in R/M Cervical Carcinoma?
03/29/2022
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study...
03/29/2022
Oncology
News
Pembrolizumab Found Beneficial in Persistent, Metastatic, or Recurrent Cervical Cancer
03/29/2022
Experts at the SGO Annual Meeting on Women's Oncology revealed adding pembrolizumab to chemotherapy ± bevacizumab provides statistically significant, clinically meaningful OS and PFS improvements in women with persistent, recurrent, or...
Experts at the SGO Annual Meeting on Women's Oncology revealed adding pembrolizumab to chemotherapy ± bevacizumab provides statistically significant, clinically meaningful OS and PFS improvements in women with persistent, recurrent, or...
Experts at the SGO Annual...
03/29/2022
Oncology
Quiz
Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer
03/27/2022
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at...
03/27/2022
Oncology
News
Novel ADC Yields Promise in FRα High, Platinum-Resistant Ovarian Cancer
03/27/2022
Mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer, according to data presented t the 2022 SGO Annual Meeting on...
Mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer, according to data presented t the 2022 SGO Annual Meeting on...
Mirvetuximab soravtansine...
03/27/2022
Oncology
Quiz
Quiz: Alternate Endocrine Therapy in Recurrent Endometrial Cancer
03/25/2022
True or false: Researchers at the SGO 2022 Meeting suggest abemaciclib plus letrozole therapy will be a very effective alternate endocrine therapy for patients with recurrent endometrial cancer whose tumors express the estrogen receptor.
True or false: Researchers at the SGO 2022 Meeting suggest abemaciclib plus letrozole therapy will be a very effective alternate endocrine therapy for patients with recurrent endometrial cancer whose tumors express the estrogen receptor.
True or false: Researchers at...
03/25/2022
Oncology
Conference Insider
Abemaciclib, Letrozole Therapy With Recurrent ER-Positive Endometrial Cancer
03/22/2022
A phase II study, presented at the 2022 SGO Annual Meeting, evaluated the combination of abemaciclib, a targeted drug, and letrozole, an aromatase inhibitor, among recurrent ER-positive endometrial cancer.
A phase II study, presented at the 2022 SGO Annual Meeting, evaluated the combination of abemaciclib, a targeted drug, and letrozole, an aromatase inhibitor, among recurrent ER-positive endometrial cancer.
A phase II study, presented at...
03/22/2022
Oncology
Conference Insider
Germline BRCA Mutations Associated With Increased Likelihood of Secondary Cytoreductive Surgery in Ovarian Cancer
03/22/2022
Experts at the 2022 SGO Annual Meeting announce germline BRCA mutation carriers are more likely to undergo secondary cytoreduction probably due to lower volume disease at recurrence.
Experts at the 2022 SGO Annual Meeting announce germline BRCA mutation carriers are more likely to undergo secondary cytoreduction probably due to lower volume disease at recurrence.
Experts at the 2022 SGO Annual...
03/22/2022
Oncology
Conference Insider
No Survival Benefit With Adjuvant Chemo or RT for Endometrial Cancer
03/30/2021
Post-operative systemic chemo and RT did not improve OS in high-risk patients with stage I endometrial cancer, according to Rachelle Findley, MD, et al.
Post-operative systemic chemo and RT did not improve OS in high-risk patients with stage I endometrial cancer, according to Rachelle Findley, MD, et al.
Post-operative systemic chemo...
03/30/2021
Oncology
Dr Boitano Reviews Minimally-Invasive vs Open Radical Hysterectomy in Early-Stage Cervical Cancer
Videos
Dr Boitano Reviews Minimally-Invasive vs Open Radical Hysterectomy in Early-Stage Cervical Cancer
03/25/2021
Teresa Boitano, MD, discusses an analysis comparing minimally-invasive hysterectomy vs open radical hysterectomy for early-stage cervical cancer.
Teresa Boitano, MD, discusses an analysis comparing minimally-invasive hysterectomy vs open radical hysterectomy for early-stage cervical cancer.
Teresa Boitano, MD, discusses an...
03/25/2021
Oncology
Conference Insider
Higher Surgery Volume Tied to Better Survival for Frail Patients With Ovarian Cancer
03/23/2021
Findings from a study presented at the 2021 SGO Virtual Annual Meeting on Women's Cancer, frail patients with ovarian cancer who undergo surgery at institutions with higher surgical volume have lower inpatient mortality rates.
Findings from a study presented at the 2021 SGO Virtual Annual Meeting on Women's Cancer, frail patients with ovarian cancer who undergo surgery at institutions with higher surgical volume have lower inpatient mortality rates.
Findings from a study presented...
03/23/2021
Oncology
Conference Insider
Rucaparib Improves PFS Versus Chemotherapy In Advanced OC with Deleterious BRCA Mutation
03/23/2021
In a session presented at the 2021 SGO Annual Meeting on Women’s Cancer Rebecca Kristeleit, PhD, UCL Cancer Institute, London, shared findings from the ARIEL4 study on rucaparib versus chemotherapy.
In a session presented at the 2021 SGO Annual Meeting on Women’s Cancer Rebecca Kristeleit, PhD, UCL Cancer Institute, London, shared findings from the ARIEL4 study on rucaparib versus chemotherapy.
In a session presented at the...
03/23/2021
Oncology
News
Durvalumab–PLD Combo Promising for Platinum-Resistant Recurrent Ovarian Cancer
04/13/2020
Durvalumab plus PLD has shown promising efficacy in patients with platinum-resistant recurrent ovarian cancer.
Durvalumab plus PLD has shown promising efficacy in patients with platinum-resistant recurrent ovarian cancer.
Durvalumab plus PLD has shown...
04/13/2020
Oncology
News
Limited Post-Surgery Opioid Prescribing Shows Potential in Patients With Gynecologic Cancers
04/13/2020
Restrictive prescribing can significantly reduce opioid use in patients with gynecologic cancers, all the while maintaining high patient pain management satisfaction.
Restrictive prescribing can significantly reduce opioid use in patients with gynecologic cancers, all the while maintaining high patient pain management satisfaction.
Restrictive prescribing can...
04/13/2020
Oncology
News
Gemcitabine–Pazopanib Combo Shows Antitumor Efficacy in Ovarian Cancer
04/13/2020
Findings from a phase 2 study showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.
Findings from a phase 2 study showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.
Findings from a phase 2 study...
04/13/2020
Oncology

The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer is the premier educational and scientific event for women’s healthcare professionals, including members of the gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiotherapy, surgery, and palliative care.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use